St Vrain Valley School District RE-1J, CO Fiscal Recovery Plan Backs Two-Notch Upgrade To 'A-' Mar 06

  • ID: 2051924
  • March 2006
  • Standard & Poors
1 of 3

DALLAS (Standard & Poor's) March 10, 2006-- Standard & Poor's Ratings Services raised its issuer credit rating on St. Vrain Valley School District No. RE-1J, Colo.'s GO debt two notches to 'A-' from 'BBB' based on management's successful implementation of a financial recovery plan, which has resulted in a positive operating performance that eliminated a $13.8 million operating deficit, or about 12% of its budget, as well as the district's improving general fund equity and liquidity position with a nearly $4.0 million positive general fund balance, or 3.3% of expenditures, in fiscal 2005 compared with a nearly negative $14.0 million in fiscal 2003. The outlook is now stable. In addition, fiscal 2005 operating results were significantly better than those indicated...

Companies mentioned in this report are: St Vrain Vy Sch Dist #RE-1J
Action: Outlook: Stable
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

St Vrain Vy Sch Dist #RE-1J

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.